Yael P Mossé
机构: University of Pennsylvania/Children's Hospital of Philadelphia
每年引用次数
引用次数
引用: 14,499
H-指数: 49
I10-指数 : 73
出版物: 164
Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)
Yael P. Mossé , Brenda J. Weigel , Charles G. Minard , Stephan D. Voss
Clinical Cancer Research
46
2021
Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.
Yael P. Mossé , Stephan D. Voss , Megan S. Lim , Delphine Rolland
Journal of Clinical Oncology 35 ( 28) 3215 -3221
145
2017
Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome
Olivia M. Padovan-Merhar , Pichai Raman , Irina Ostrovnaya , Karthik Kalletla
PLOS Genetics 12 ( 12) e1006501
51
2016
Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study
Yael P. Mossé , Emily Lipsitz , Elizabeth Fox , David T. Teachey
Clinical Cancer Research 18 ( 21) 6058 -6064
137
2012
The ALK/ROS1 inhibitor PF-06463922 overcomes primary resistance to crizotinib in ALK-driven neuroblastoma
Nicole R. Infarinato , Jin H. Park , Kateryna Krytska , Hannah T. Ryles
Cancer Discovery 6 ( 1) 96 -107
95
2016
Chromosome 1p and 11q deletions and outcome in neuroblastoma.
Edward F. Attiyeh , Wendy B. London , Yael P. Mossé , Qun Wang
The New England Journal of Medicine 353 ( 21) 2243 -2253
399
2005
Inhibition of ALK signaling for cancer therapy.
Yael P. Mossé , Andrew Wood , John M. Maris
Clinical Cancer Research 15 ( 18) 5609 -5614
134
2009
Thrown for a Loop: Awakening BORIS to Evade ALK Inhibition Therapy.
Esther R. Berko , Yael P. Mossé
Cancer Cell 36 ( 4) 345 -347
2019
Advances and Challenges in Pediatric and Childhood Cancers
Cynthia Hawkins , Stefan Pfister , David T.W. Jones , Nirali N. Shah
Cancer Cell 38 ( 4) 429 -432
2020
Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies.
Yael P. Mossé
Clinical Cancer Research 22 ( 3) 546 -552
36
2016
Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.
Kateryna Krytska , Hannah T Ryles , Renata Sano , Pichai Raman
Clinical Cancer Research 22 ( 4) 948 -960
52
2016
Targeting ALK in neuroblastoma--preclinical and clinical advancements.
Erica L. Carpenter , Yael P. Mossé
Nature Reviews Clinical Oncology 9 ( 7) 391 -399
112
2012
An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma
Renata Sano , Kateryna Krytska , Colleen E. Larmour , Pichai Raman
Science Translational Medicine 11 ( 483)
16
2019
A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)
Yael P. Mossé , Elizabeth Fox , David T. Teachey , Joel M. Reid
Clinical Cancer Research 25 ( 11) 3229 -3238
59
2019
Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT‐751: A report from the Children's Oncology Group (ANBL0621)
Elizabeth Fox , Yael P. Mosse' , Holly M. Meany , James G. Gurney
Pediatric Blood & Cancer 61 ( 6) 990 -996
14
2014
ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma
Scott C. Bresler , Daniel A. Weiser , Peter J. Huwe , Jin H. Park
Cancer Cell 26 ( 5) 682 -694
196
2014
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
Yael P Mossé , Megan S Lim , Stephan D Voss , Keith Wilner
Lancet Oncology 14 ( 6) 472 -480
704
2013
OTHR-02. CHIMERIC AURORA A KINASE (AURKA) DEGRADERS EFFICIENTLY TARGET N-MYC
Gintvile Valinciute , Lorenz Eing , Jeffrey Mihalic , Colleen E Casey
Neuro-Oncology 25 ( Supplement_1) i73 -i74
2023
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: Phase 1 trial results
Kelly C Goldsmith , Julie R Park , Kimberly Kayser , Jemily Malvar
Nature medicine 29 ( 5) 1092 -1102
45
2023
Serial profiling of circulating tumor DNA identifies dynamic evolution of clinically actionable genomic alterations in high-risk neuroblastoma
Kristopher R Bosse , Anna Maria Giudice , Maria V Lane , Brendan McIntyre
Cancer discovery 12 ( 12) 2800 -2819
24
2022